OriGene Technologies, Inc.
  邮箱:  密码: 忘记密码?
注册 | 购物车 | 主页
搜索:    
About FL cDNA Clones RNAi Gene Expression Lysates and Proteins Antibodies Tissue IVD 原料 Other Products Tech Support
orange


Primer

Page 1 of 36


Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy, Gao, J;Shi, LZ;Zhao, H;Chen, J;Xiong, L;He, Q;Chen, T;Roszik, J;Bernatchez, C;Woodman, SE;Chen, PL;Hwu, P;Allison, JP;Futreal, A;Wargo, JA;Sharma, P;, Cell 2016 IFNGR1

MicroRNA signatures of colonic adenomas according to histology, Tsikitis, VL;Potter, A;Mori, M;Buckmeier, JA;Preece, CR;Harrington, CA;Bartley, AN;Bhattacharyya, A;Hamilton, SR;Lance, P;Thompson, PA;, Cancer Prev Res (Phila) 2016 MIR143

MicroRNA signatures of colonic adenomas according to histology, Tsikitis, VL;Potter, A;Mori, M;Buckmeier, JA;Preece, CR;Harrington, CA;Bartley, AN;Bhattacharyya, A;Hamilton, SR;Lance, P;Thompson, PA;, Cancer Prev Res (Phila) 2016 MIR145

MicroRNA signatures of colonic adenomas according to histology, Tsikitis, VL;Potter, A;Mori, M;Buckmeier, JA;Preece, CR;Harrington, CA;Bartley, AN;Bhattacharyya, A;Hamilton, SR;Lance, P;Thompson, PA;, Cancer Prev Res (Phila) 2016 MIR93

miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells, Venza, M;Visalli, M;Beninati, C;Benfatto, S;Teti, D;Venza, I;, Int. Immunopharmacol. 2016 MYCBP2

NLRC4 suppresses melanoma tumor progression independently of inflammasome activation, Janowski, AM;Colegio, OR;Hornick, EE;McNiff, JM;Martin, MD;Badovinac, VP;Norian, LA;Zhang, W;Cassel, SL;Sutterwala, FS;, J. Clin. Invest. 2016 CXCL10

NLRC4 suppresses melanoma tumor progression independently of inflammasome activation, Janowski, AM;Colegio, OR;Hornick, EE;McNiff, JM;Martin, MD;Badovinac, VP;Norian, LA;Zhang, W;Cassel, SL;Sutterwala, FS;, J. Clin. Invest. 2016 CXCL16

NLRC4 suppresses melanoma tumor progression independently of inflammasome activation, Janowski, AM;Colegio, OR;Hornick, EE;McNiff, JM;Martin, MD;Badovinac, VP;Norian, LA;Zhang, W;Cassel, SL;Sutterwala, FS;, J. Clin. Invest. 2016 CXCL9

NLRC4 suppresses melanoma tumor progression independently of inflammasome activation, Janowski, AM;Colegio, OR;Hornick, EE;McNiff, JM;Martin, MD;Badovinac, VP;Norian, LA;Zhang, W;Cassel, SL;Sutterwala, FS;, J. Clin. Invest. 2016 IFNG

Notch hyper-activation drives trans-differentiation of hESC-derived endothelium, Reichman, D;Man, L;Park, L;Lis, R;Gerhardt, J;Rosenwaks, Z;James, D;, Stem Cell Res 2016 LFNG
  Next >  View All   
全国免费电话:400-6744-363(手机),800-9904-363(座机)订货邮箱:orderscn@origene.com,techsupport@origene.cn
电话:+86-10-59755312 传真:+86-10-59755322-888 地址:北京市经济技术开发区科创14街99号汇龙森科技园11栋
京ICP证07031721号 Copyright © 2017 北京傲锐东源(OriGene Technologies)生物科技有限公司,All Rights Reserved. 法律声明.